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Combining micro-RNA and protein 
sequencing to detect robust 
biomarkers for Graves’ disease and 
orbitopathy
Lei Zhang1, Giulia Masetti1,2, Giuseppe Colucci3, Mario Salvi 3, Danila Covelli3,  
Anja Eckstein4, Ulrike Kaiser4, Mohd Shazli Draman 1, Ilaria Muller 1, Marian Ludgate1, 
Luigi Lucini 5 & Filippo Biscarini 1,6
Graves’ Disease (GD) is an autoimmune condition in which thyroid-stimulating antibodies (TRAB) 
mimic thyroid-stimulating hormone function causing hyperthyroidism. 5% of GD patients develop 
inƪammatory Graves’ orbitopathy (GO) characterized by proptosis and attendant sight problems. 
A major challenge is to identify which GD patients are most likely to develop GO and has relied on 
TRAB measurement. We screened sera/plasma from 14 GD, 19 GO and 13 healthy controls using 
high-throughput proteomics and miRNA sequencing (Illumina’s HiSeq2000 and Agilent-6550 Funnel 
quadrupole-time-of-ƪight mass spectrometry) to identify potential biomarkers for diagnosis or 
prognosis evaluation. Euclidean distances and diơerential expression (DE) based on miRNA and 
protein quantiƤcation were analysed by multidimensional scaling (MDS) and multinomial regression 
respectively. We detected 3025 miRNAs and 1886 proteins and MDS revealed good separation of the 3 
groups. Biomarkers were identiƤed by combined DE and Lasso-penalized predictive models; accuracy 
of predictions was 0.86 (±0:18), and 5 miRNA and 20 proteins were found including Zonulin, Alpha-2 
macroglobulin, Beta-2 glycoprotein 1 and Fibronectin. Functional analysis identiƤed relevant metabolic 
pathways, including hippo signaling, bacterial invasion of epithelial cells and mRNA surveillance. 
Proteomic and miRNA analyses, combined with robust bioinformatics, identiƤed circulating biomarkers 
applicable to diagnose GD, predict GO disease status and optimize patient management.
Prevention is better than cure, a maxim which applies to all diseases and has led to eorts to identify biomarkers 
dened by the National Institutes of Health as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic inter-
vention”1. e discovery of biomarkers is one example of the translation of fundamental research into clinical 
applications. On one hand it helps elucidate disease aetiology and mechanisms, on the other hand biomarkers can 
be useful clinical tools (diagnosis, prognosis, therapy indications etc)2,3. Initial attempts to discover biomarkers 
were based on immunoassays (e.g. ELISA) or hybridization microarrays4. ‘Omics data from high-throughput 
next-generation sequencing (NGS) technology are now increasingly used for biomarker screening5,6. Biomarkers 
can be detected from several tissues and uids, such as urine7, saliva8, swabs9, and blood10,11. Blood biomarkers 
were originally screened in relation to blood and cardiometabolic diseases, but also found applications in systemic 
conditions like cancer, infections, degenerative diseases and autoimmune conditions12–15.
Graves’ orbitopathy (GO) is an eye disease occurring mainly in patients with Graves’ disease (GD), in which 
autoantibodies (TRAB) to the thyrotropin receptor (TSHR) cause hyperthyroidism. GD is associated with 
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considerable genetic susceptibility16, including polymorphisms in the TSHR and CD40 genes, with the latter 
leading to cytokine imbalance in the thyroid17. In GO, inammation with subsequent remodelling and expan-
sion of orbital tissues leads to proptosis accompanied by corneal exposure, diplopia etc., and may even result 
in blindness. Moderate GO occurs in 30–50% of GD patients, but the most severe eye condition is found in 5% 
of patients18,19. One of the challenges has been to identify which GD patients are most likely to develop GO: 
elevated serum TRAB have been correlated to the severity of GO20, and high TRAB combined with low/absent 
autoantibodies to thyroid peroxidase potentially identify such patients21. Blood biomarkers for GD and GO may 
facilitate the diagnosis and follow-up (i.e. monitoring progression) of patients, identifying individuals most likely 
to develop the eye condition. Currently, the diagnosis of GD relies on examination of the thyroid, measurement 
of serum thyroid hormones concentrations and TRAB assay, while predicting the progression from GD to GO 
is imperfect and relies mostly on clinical signs. Biomarkers could complement diagnosis and monitoring of this 
disease by: (i) increasing accuracy, (ii) reducing costs, (iii) speeding up time to diagnosis. Additionally, the loss of 
immune-tolerance mechanisms in GD/GO is poorly understood.
Circulating proteins and microRNA (miRNA) are the two most widely used classes of blood biomarkers for 
clinical research; for miRNA, this is linked to their emerging mechanistic role in specic disorders, e.g. metabolic 
and cardiovascular diseases22 and cancer23. In GO, proteomics approaches have been applied to compare the 
protein proles of tears from GO patients with healthy controls24,25, GD patients free of eye disease26, smokers27
and people with dry-eye syndrome28. At present, there are no reports of proteomic proling of serum or plasma 
in GO patients and the only investigation of circulating miRNA has focussed on non-responders to glucocorti-
coid therapy29. Hence, we aimed to apply high throughput proteomics and analysis of miRNA in serum to search 
for biomarkers that can be used to predict GO and plan the most appropriate treatment regimen. Together with 
the analysis of dierential expression in patients and healthy controls, blood miRNAs and proteins data have 
also been used to predict which group (either GD, GO, healthy controls) the individual samples belonged to. By 
complementing results from dierential expression and the predictive model, robust candidate biomarkers have 
been identied.
Methods
Ethics statement. All samples were collected between October 2014 and June 2016 within the framework of 
the EU-FP7 Indigo project (http://www.indigo-iapp.eu/): appropriate local research ethical approval and written 
informed consent was obtained from all participants.[Essen: Ethik-Kommission reference 14-5965-BO; Cardi: 
Wales Research Ethics reference 12/WA/0285; Milan: Comitato Etico Milano Area B, approval obtained on 
11/11/2014]. All subjects were treated in accordance with the tenets of the Declaration of Helsinki. e INDIGO 
study enrollment criteria were: (i) newly diagnosed or relapsing GD patients under anti thyroid treatment within 
six weeks from the onset of hyperthyroidism, (ii) GD patients at euthyroidism, (iii) newly diagnosed GD patients 
with overt GO.
Experimental samples. From a larger cohort of patients and healthy controls recruited by the INDIGO 
project, 46 caucasian females (33 cases, 13 controls) were selected for miRNA and proteomics sequencing. Cases 
were further subdivided into Graves’ disease patients with (GO=19) and without (GD=14) orbitopathy. Patients 
were treatment naive or within 6 weeks of commencing antithyroid drug therapy. e clinical activity score of 
GO was assessed following EUGOGO guidelines30. Healthy controls were all free of thyroid disease, euthyroid 
and negative for TRAB. Cases and controls were recruited in three medical centres from dierent European 
countries: Cardi University Hospital (United Kingdom), Essen University Hospital (Germany), and University 
of Milan (Italy). As far as possible, cases and controls were matched by age to limit external confounders. Table 1
summarizes the characteristics of the patients and controls used. Blood samples were collected from all subjects 
enrolled either in EDTA-coated test tubes for plasma or gel-lled test tubes for serum separation (BD Vacutainer), 
and processed by centrifugation at 1200g for 15min within one hour from collection, then stored at −20 °C until 
used. Samples from patients with GD and GO were obtained at the rst hospital visit or when they relapsed: both 
Centre Statusa N orbitopathyb age smokersc
TSH 
(mIU/L)
TRAB 
(IU/L)
FT4 
(pmol/L)
Cardi control 4 53±21.1 0 0.92 0.00 14.62
Cardi GD 5 51.6±17.9 3 0.02 9.68 23.64
Cardi GO 6 4/2/0 61.3±16.1 2 0.67 6.60 19.36
Essen control 5 47.2±11.7 1 2.00 0.30 12.70
Essen GD 5 40.8±10.9 3 0.01 12.71 33.12
Essen GO 8 1/3/4 48.4±10.6 6 0.32 11.41 17.96
Milano control 4 50.2±2.2 0 1.50 0.40 11.00
Milano GD 4 57.5±17.1 0 0.01 10.72 30.13
Milano GO 5 2/3/0 47.2±14.8 1 0.45 16.25 17.36
Table 1. Recruiting centre, disease status, age (years), smoking habit and mean serum biochemical parameters 
of patients and controls enrolled for this study (all females, all caucasians). aGD: Graves’ disease; GO: Graves’ 
orbitopathy; bOrbitopathy: N=number of mild/moderate/sight-threatening GO cases; csmokers were dened 
as current or previous smokers.
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conditions were diagnosed by the presence of suppressed blood TSH (thyroid-stimulating hormone), FT4 (free 
thyroxine) levels above the local reference range, TRAB positivity, and diuse goitre (when present).
microRNA sequencing. miRNAs were extracted from plasma samples using NucleoSpin miRNA Plasma 
kit, following manufacturer’s instructions. Quantification and integrity of the nucleic acid were assessed 
with NanoDrop 1000 spectrophotometer (ermo Scientic) and Agilent 2200 TapeStation system (Agilent 
Technologies), respectively, to check the requirements for library preparation. For each sample library, 5µL of 
extracted small RNA were used in all the experimental procedures. Each library was prepared with the Truseq 
SmallRNA kit (Illumina Inc., USA) with minor modications to the manufacturer’s protocol. In order to mini-
mize primer dimers formation, small RNA was introduced into half of the TruSeq Small RNA Sample reagents 
followed by 15 cycles of PCR to amplify the library. 10µL of unique indexed libraries was pooled and resolved on a 
Pippin Gel cassette 3% Agarose Dye free (BluePippin, Sage Science, MA, USA). DNA fragments from 140−160bp 
(the length of miRNA inserts plus the 3′ and 5′ adaptors) were recovered in 40µL of Pippin elution buer and 
then puried by Qiagen MinElute PCR Purication kit (Qiagen, CA, USA). e indexed libraries were quantied 
with ABI9700 qPCR instrument using the KAPA Library Quantication Kit in triplicates, according to the manu- 
facturer’s protocol (Kapa Biosystems, Woburn, MA, USA). 10µL of the pooled library at a nal concentration of 
2nM were used for sequencing using Illumina HiSeq. 2000 with a 50 Single-Read sequencing module in a total 
number of 4 lanes.
Nano LC/QTOF proteomic mass-spectrometry. Serum samples (35 µL) were processed through 
the ProteoExtract® Albumin/IgG removal kit (Calbiochem®) according to manufacturer instructions, before 
proteomic analyses. Protein content was next determined in the eluted extracts through the Bio-Rad Protein 
Assay kit (Bio-Rad, Hercules, CA, USA) with bovine γ-globulin as standard. en, 50µg proteins were loaded 
in 4−20% TGX Stain-Free TM precast mini gel (Bio-Rad) and subjected to SDS-PAGE electrophoresis (Bio-Rad 
MiniPROTEAN® Tetra Cell) to achieve a rough fractionation. e lanes from each sample were manually cut 
into four slices of the same size, and proteins were reduced with DTT, alkylated with iodoacetamide and over-
night digested using trypsin (Promega, Madison, WI, USA). Tryptic peptides were analysed using nanoscale 
liquid chromatography coupled to a hybrid quadrupole-time-of-ight (Q-TOF) mass spectrometer, as previously 
reported31. With this aim, a nano LC Agilent 1260 Chip Cube source and an Agilent 6550 IFunnel Q-TOF mass 
spectrometer (Agilent Technologies, Santa Clara, CA, USA) were used. Briey, peptides were enriched onto a 
C18 trapping column and backush eluted into a 150mm separation column (ProtID chip, Zorbax 300SB-C18, 
5µm pore size). An acetonitrile gradient (from 3 to 70% v/v in 50min, then hold for 15min) in 0.1% (v/v) formic 
acid was adopted for elution, with mobile phase owing at 0.3µL min−1. e QTOF was operated in tandem 
MS data-dependent acquisition and positive ionization mode; MS SCAN was done in the range from 300 to 
1700m/z, with 4 spectra s−1. A maximum of 20 precursors per cycle were selected for tandem MS fragmenta-
tion, using precursors absolute threshold of 1000 and a relative threshold of 0.001. MS/MS spectra of peptides 
were used for protein inference via database searching in Spectrum Mill MS Proteomics Workbench (Rev B.04; 
Agilent Technologies). Carbamidomethylation of cysteine was set as a xed modication while trypsin selected 
as enzyme for protein digestion, accepting two missed cleavages per peptide. Inference was set with the following 
parameters: Scored Peak Intensity (SPI)≥50%, precursor mass tolerance of ±10ppm and product ions mass tol-
erance of ±20ppm. e search was conducted against the proteome of Homo sapiens (UniProt, downloaded July 
2016). e database was concatenated with the reverse one and 1% false discovery rate was selected for validation 
purposes. Finally, a label-free quantitation was carried out using summed peptide abundance.
Bioinformatics processing and data normalization. Fastq les resulted from miRNA sequencing were 
rst checked for sequence quality in terms of GC content, duplication level, length and Phred score. Reads were 
trimmed on base-call quality (Phred score >15 over a 4bps sliding-window; this gives a probability lower than 
0.03 that a base is called incorrectly; see Ewing et al.32 for details on Phred) and length >15 bps, as miRNAs 
usually have length in the range 20−22bps. Adapters used for reverse transcription and amplication were also 
trimmed o the reads. Trimmed reads were used along with the human reference genome (assembly GRCh38) 
and a database of known mature miRNA and precursors to detect known and novel miRNAs in each sample. 
miRNA detection and quantication was carried out using the miRDeep2 algorithm33; both novel and known 
miRNAs were quantied in terms of counts per sample. All miRNA bioinformatics processing was streamlined 
using an informatic pipeline developed in-house at the Bioinformatics Unit of PTP Science Park (www.ptp.it).
RNA sequencing is known to be highly variable across samples, and normalization for library size (the total 
amount of sequences per sample) is therefore recommended before analysing count data. miRNA raw counts 
were converted within each sample to counts-per-million (CPM)34:
= ⋅CPM X
N
10 (1)i
i 6
where, for each sample, CPMi and Xi are, respectively, the counts-per-million and raw counts for miRNA i, and 
N is the total number of reads sequenced in the sample. Only miRNAs with CPM≥2 in more than two samples 
were retained for subsequent analyses.
Raw protein abundances from mass-spectrometry were normalized through log-transformation:
=




=
>
f x
x
log x x
( )
0 if 0
( ) if 0 (2)
i
i
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where xi is the protein raw abundance, and log() is the Napierian logarithm35. Only proteins expressed (xi>0) in 
more than two samples were retained for subsequent analyses.
Cluster analysis. Metric multidimensional scaling (i.e. Principal Coordinate Analysis36) of dissimilarity 
matrices based on miRNA and proteomics data was used to visualize how GD/GO patients and controls clus-
tered in a Cartesian coordinate system. Euclidean distances between samples were estimated based on normal-
ized and ltered: (i) miRNA counts, (ii) protein abundances, and (iii) miRNA counts and protein abundances 
combined together. Distances matrices were scaled and centered and their eigenvalues used to order principal 
coordinates by the proportion of variability they captured. e clustering obtained by the three distance matrices 
was compared.
Diơerential expression of miRNAs and proteins. To detect miRNA dierential expression and protein 
dierential abundance in blood samples between the three groups (GD, GO, controls), two dierent models were 
tted for miRNA and protein data separately. miRNA counts were modeled by a negative binomial (NB) distri-
bution to account for overdispersion relative to a one-parameter Poisson distribution. e following generalized 
linear model with log-link function was tted:
µ= + + +log y status centre e( ) (3)ijqk i j q ijqk
where yijqk are miRNA i counts for individual k with status j from centre q. Residuals -and observations- are 
negative-binomially distributed deviates as ~ µ σz NB( , )ik i i
2 , with µi the average expression for miRNA i, and σi
2
its variance, given by µi(1+φiµi), where φi is the miRNA-specic dispersion parameter (when φ= 0, the NB 
distribution reduces to Poisson). Protein relative abundances were analysed through a multinomial logarithmic 
regression model, where the probability of individual samples to belong to any of the three classes (GD, GO, con-
trol) was modeled as:
= | =
∑
η
η
=
P Y k X e
e
( )
(4)l
K
1
k
l
where P(Y=k|X) is the probability of sample Y to belong to class k given its vector of features X (log-transformed 
protein abundances and centre of origin), and ηk is a linear predictor of the form µk+β1kCentre+β2k protein, with 
class-specic mean and regression coecients for the centre and any protein i. A generalized linear model with 
log-link function was used to t the data:
∑η η= | = − η
′∈
′logP Y k X log( )
(5)k k K
k
where η∑ η′∈ ′log k K k  is a normalization constant to ensure that results will form a probability distribution (i.e. sum 
to one). Both for Equations (3) and (5) the likelihood ratio test between the full models and reduced models 
without the “status” and “protein” terms, respectively, was performed to assess signicance for any tested miRNA 
or protein. e false discovery rate (FDR37) was used to monitor false positives, expressing results in terms of the 
empirical Bayesian probability that the null hypothesis is true conditional on the observed p-value 
(P(H0=TRUE|p-value)).
e power of dierential expression analysis depends on the sample size, the depth of sequencing and the 
magnitude of the dierential expression between groups. Following Hart et al.38, the sample size (n) necessary to 
achieve a pre-specied statistical power of analysis can be calculated from the equation below:
σ
= ⋅ +
+
∆
α β
µ
−( ) ( )n z z log2 ( ) (6)e1 2
2
1 2
2
where −αz1 2  and zβ are the Gaussian deviates corresponding to the desired false positive (α) and false negative (β) rates; µ is the average coverage (depth of sequencing); σ is the coecient of variation of the number of reads 
across groups; ∆ is the (expected) dierential expression (i.e. fold-change); and loge is the Napierian logarithm. In 
the case of miRNAs, it is dicult to speak strictly of “coverage”; however, sequencing protocols for small RNA 
suggest the target of 1–2 million usable miRNA reads per sample, which can be achieved by sequencing 10 million 
reads per sample on average. is is what was done in the present study, giving a coverage of approximately 10. 
e estimated coecient of variation of sequences across samples was 0.23 for miRNA and 0.35 for proteins. For 
dierentially expressed genes with a fold-change of 2, Equation 6 would give a sample size between 4 and 8 indi-
viduals per group for a false positive rate (α) of 0.05 and a power (β) in the range 0.7−0.9.
‘omics predictive models. microRNA counts and protein relative abundances were also used for the clas-
sication problem of predicting whether individuals, based on their proles, belonged to the GD, GO or control 
class. Multinomial logistic regression was used to model the posterior probabilities of the three classes P(Y=k|X), 
as in Equations (4) and (5). ree models were tested: (i) miRNA counts only; (ii) protein abundances only; (iii) 
miRNA and protein data combined. Unlike in the dierential expression analysis, here miRNA and proteins were 
not analysed separately, one by one, rather included all together in the feature matrix X. e eect of centre of 
origin (Cardi, Essen, Milan) was also included, in all three models. Since the number of parameters p (miRNA, 
proteins, miRNA+proteins) was always much larger than the number of individuals n, an L1 penalization was 
added to the log-likelihood function used to solve the model:
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where θ is the vector of parameters (coecients) over the K=3 classes; N is the sample size, yil= I(ki= l) is an 
indicator variable specifying to which class the observation yi belongs; λ is the penalization hyperparameter -to 
be tuned- that controls the degree of regularization. Equation 7 was solved with a partial-Newton algorithm via 
coordinate descent39.
L1-penalized Lasso (least absolute shrinkage and selection operator) models, besides allowing for solutions of 
p n problems, have the property of selecting variables (miRNA and proteins, in our case) to be included in the 
model, by setting some of the coecients exactly equal to zero. On one hand, this makes matrix X sparse, thus 
speeding up computation; on the other hand, it natively returns a list of relevant predictors (variable included in 
the predictive model). To estimate the predictive ability of the tested Lasso-penalized multinomial logistic regres-
sion models, data were rst split into a test set (1/10 of the data), where accuracy was measured, and a training set 
(9/10 of the data), where the model was trained, i.e. the coefficients estimated. In the training set, the λ
Lasso-penalization coecient was tuned through 10-fold cross-validation40. e nal model from cross-validation 
was applied to the test set, and the overall and per-class error rates were obtained. e whole process was repeated 
150 times, each time randomly resampling new test and training sets, in order to obtain robust estimates of the 
model’s predictive ability and reliability (variability of predictions).
Functional and pathway analysis. Candidate biomarkers identied from dierential expression anal-
ysis and predictive models, have been further analysed by querying biological databases for related annotated 
functions and pathways. For proteomics data, UniProt protein identiers (http://www.uniprot.org/) were con-
verted to corresponding HGNC (Human Genome Organisation Gene Nomenclature Committee, https://www.
genenames.org/) gene symbols. Candidate novel miRNA sequences were aligned against the reference human 
genome build 38 (GRCh38) and against the corresponding transcriptome (GRCh38, cDNA) using the Basic Local 
Alignment Search Tool (BLAST41). From annotated alignments, HGNC gene symbols were obtained. Both lists of 
gene symbols were then used to search for related functions and metabolic pathways. Based on genes annotated 
to metabolic pathways in the KEGG database (http://www.kegg.jp), an enrichment analysis for the identied 
candidate biomarkers was conducted, to detect pathways signicantly associated with the corresponding genes 
(protein-coding genes and miRNA targets). is was determined based on a hypergeometric distribution, on the 
underlying assumption of no association (random distribution of genes and pathways):
∑= −
=
−
−
−( )( )
( )
p 1
(8)i
k
M
i
N M
n i
N
n0
1
where p is the p-value for the association between any specic pathway and the candidate biomarkers gene-set; 
N and M are the total number of annotated genes, and total number of genes annotated to any specic pathway, 
respectively, in the KEGG database; n is the size of the candidate-biomarkers list of genes; k is the number of 
candidate-biomarkers genes annotated to any specic pathway. e summation refers to the probability of ran-
domly observing up to k−1 genes annotated to any specic pathway (the hypergeometric cumulative distribution 
function), whose complement to one gives the probability of not observing, by chance alone, k genes associated 
to that pathway (the p-value).
Software. Quality check of FastQ les from miRNA sequencing was performed using the FastQC soware42; 
to trim miRNA reads the programme Trimmomatic43 was used, while the Perl programme suit miRDeep2, devel-
oped at the Max Delbrück Center for Molecular Medicine (https://www.mdc-berlin.de/8551903/en/), was used 
to align and count known and novel miRNAs. e R packages edgeR44 and qvalue45 were used for dierential 
expression analysis and the estimation of FDR; the R package ggplot246 was used for all gures. BLAST 2.2.26 for 
Linux was used for sequence alignments to nd miRNA targets. e R environment for statistical programming 
and Python were used for data processing and manipulation and for accessory data analysis.
Data availability. e datasets generated by the current study are available from the corresponding author 
upon request.
Results
Analysis of sequenced miRNA and proteins. We obtained 28GB of Fastq miRNA les demonstrating 
overall good sequencing quality (FastQC). On average, 13069923 reads per sample were sequenced, with an 
average length of 23.31bps. Aer trimming (with parameters: Phred >15, length >15bps, adapters), 52.4% of the 
reads were retained. Querying the miRDeep2 database with trimmed reads, and alignment against the human 
reference genome, yielded a total of 3025 miRNAs (1881 known, 1144 novel). Filtering for CPM≥ 2 in more 
than two samples le 1332 miRNA available for subsequent analyses (777 known, 555 novel). From proteomic 
mass-spectrometry, 1886 proteins were detected which reduced to 831 proteins retained for analyses aer ltering 
for proteins expressed in >2 samples.
Cluster analysis. Distances between samples (GD, GO and controls) were estimated from miRNA counts 
and protein relative abundances. ree Euclidean distance matrices were compared: based on miRNA, proteins 
and miRNA+proteins combined. Clearly separate clusters were not obtained from miRNA counts alone, while 
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protein abundances and, especially, proteins and miRNA data combined did form separate clusters (77.3% of total 
variation accounted for by the rst two dimensions from multidimensional scaling). In particular, controls were 
clearly distinguished from Graves’ disease cases, while a less clear boundary between GD and GO patients was 
obtained (Fig. 1).
Diơerential expression analysis. We demonstrated 27 miRNAs (12 known, 15 novel) and 178 proteins 
with dierential expression (FDR<0.05) between GD, GO and control groups, as reported in Supplementary 
Table 1. Highest fold changes were observed between GD and controls (average 1.69), followed by GO vs controls 
(average 1.36), with least dierential expression between GD and GO patients (average 1.01). e top known and 
novel miRNAs were hsa-mir-497, hsa-mir-320b-1 and hsa-mir-320b-2, up-regulated in GD, Novel:19_15038 and 
Novel:hsa-miR-27a-3p up-regulated in GO, and Novel:hsa-miR-22-3p which was down-regulated in GD and 
GO. ree of the four most dierentially expressed proteins were up-regulated in GD (haptoglobin-related pro-
tein, haptoglobin–zonulin–and zinc-alpha-2-glycoprotein), except the coiled-coil domain-containing protein 25 
which was down-regulated in GD and GO. Immunoglobulins (n=19), kinases (n=12) and complement-related 
proteins (n=12) had the highest frequency among the 155 proteins with FDR<0.05.
ClassiƤcation accuracy. ree ‘omics lasso-penalized multinomial logistic regression models were com-
pared for the classication of individual samples into the three classes (GD, GO, controls): (i) a model based only 
on blood miRNA counts; (ii) a model based only on blood protein relative abundances; (iii) a model based on 
combined blood miRNA and proteins data. e accuracy of classication is reported in Table 2, overall and per 
class. e error rate (1-accuracy) of the three models, either overall or per-class, is shown in Fig. 2: the closer to 
the centre the points lie, the better the predictive ability of the model. e spread around the centre of the target 
indicates the variability of predictions over the 150 replicates of each model: the less variable, the more reliable. 
In general, all models behaved well in terms of predictive ability, with overall average accuracy in the range 
0.712−0.863. However, the average classication accuracy clearly increased when miRNA and proteins were used 
together in the model, and the standard deviation decreased (more reliable predictions). To ensure that overall 
accuracy was not driven by one of the three classes, the within-class accuracy was also evaluated. In general clas-
sication, models predicted equally well samples belonging to all classes. Predictions based on miRNA alone were 
substantially more variable (standard deviation 0.303, 0.337 and 0.341 in controls, GD and GO, respectively). 
Models based on proteins and, especially, the proteins and miRNA combined, produced higher and more stable 
prediction accuracy in all classes. In particular, the miRNA+proteins model had an average error rate of 7.2% 
in GO patients.
Lasso models natively operate variable selection: this means that in each of the 150 replicates of the three 
‘omics models, a subset of miRNA, proteins or a mix of miRNA and proteins was selected for classication. is 
way, the proportion of times each predictor (miRNA or protein) was selected over the 150 replicates could be 
calculated. Supplementary Table 2 reports all predictors used by the three models, along with their frequency. 
In total, 127 miRNAs, 87 proteins, and 90 between miRNA (45) and proteins (45) were used by the miRNA, 
proteins and miRNA+proteins models. Frequencies>90% were obtained for three miRNAS (Novel:19_15038 
(0.98), Novel:hsa-miR-6748-3p (0.98), hsa-mir-887 (0.97)) and two proteins (haptoglobin (zonulin): 0.99) and 
alpha-2-macroglobulin (0.99)).
Figure 1. Multidimensional scaling (MDS) plots of distance matrices based on miRNA counts (le), proteins 
abundances (centre), miRNA and proteins together (right) from blood samples taken from Graves’ disease and 
orbitopathy patients and healthy controls. dim1, dim2: the rst two dimensions from MDS.
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Biomarker discovery. Results from differential expression and classification models were combined 
together to detect robust potential blood biomarkers for GD and GO. Five sets of candidate biomarkers were 
considered: results from dierential expression analysis of miRNA and proteins with FDR lower than 5% (mirDE 
and protDE), 20 top-ranked predictors -in terms of frequency of inclusion- each for the miRNA, proteins and 
miRNA+proteins classication models (mirPRD, protPRD, mir+protPRD). e intersections of these sets were 
combined in a single list of potential biomarkers as from the set expression below:
label model accuracy std
all miRNA 0.71 0.21
all proteins 0.81 0.19
all miRNA+proteins 0.86 0.18
control miRNA 0.82 0.30
control proteins 0.90 0.21
control miRNA+proteins 0.86 0.27
GD miRNA 0.68 0.34
GD proteins 0.84 0.21
GD miRNA+proteins 0.78 0.30
GO miRNA 0.68 0.34
GO proteins 0.81 0.22
GO miRNA+proteins 0.93 0.14
Table 2. Classication accuracy (total and per class) from Lasso-penalized logistic regression models based 
on miRNAs and proteins separately, and on miRNAs and proteins combined. e standard deviation of 
classication accuracy (over the 150 repetitions of each predictive model) is also reported.
Figure 2. Error rates (1-accuracy) from ‘omics predictive models. (a) Total error rate with the three models 
(miRNA, proteins, miRNA+proteins); (b) Per-class (controls, GD, GO) error rates with the three models 
(dierent sections of the target). Black (a) and coloured (b) circles indicate average error rates, per model 
(above) and per class (below). Colours of the average error rate in the below graphs represent the models 
(miRNA, proteins and miRNA+proteins).
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∩ ∪ ∩ ∪ ∩ ∪+(mirDE mirPRD) (protDE protPRD) (mir protPRD (mirDE protDE)) (9)
e Euler diagram of the ve sets of candidate biomarkers is reported in Fig. 3. Five miRNA (mirDE∩mir-
PRD), 17 proteins (protDE∩protPRD) and a mix of 15 miRNA and proteins (mir+protPRD∩ (mirDE∪pro-
tDE)) were in common between results from dierential expression and Lasso classication models. Twenty-ve 
out of these 37 biomarkers were unique (non-duplicated), and provided the list of robust biomarkers for Graves’ 
disease and Graves’ orbitopathy detected in this work (Table 3). Figure 4 shows the heatmap of pairwise log2
fold-change (logFC) for the identied biomarkers listed in Table 3.
miRNA targets. e ve novel miRNAs selected as candidate biomarkers were aligned against the human 
genome and transcriptome to search for potential targets. miRNA molecules are known to regulate gene expres-
sion. In total, 57 target genes were detected from genome alignments, with 99.7% average sequence identity 
(median=100%), and 0.29 average (median 0.16) e-value (expected number of matches to be obtained by chance 
alone against the human genome). From transcriptome alignments, two proteins (phosphatase and actin regula-
tor 3; protocadherin-16) and four unannotated loci were detected, with an average identity and e-value of 100% 
and 0.32, respectively. Comprehensive details on miRNA targets are listed in the Supplementary Table 3.
Metabolic pathway analysis. Pathways associated with the candidate biomarkers were identied using 
the KEGG (Kyoto Encyclopedia of Genes and Genomes) database of human genes and annotated metabolic 
pathways. ey were ordered by the signicance of association (Fig. 5) with the top 5 pathways for miRNA alone, 
protein alone and miRNA/protein combined reported in Table 4. In the combined group there were 16 path-
ways with p-value≤0.05 (from Equation 8). ese included: regulation of actin cytoskeleton, PI3K-Akt signaling 
pathway, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Hypertrophic cardiomyopathy (HCM), 
Dilated cardiomyopathy (DCM), Cell adhesion molecules (CAMs), Oxytocin signaling pathway, Focal adhesion, 
Hippo signaling pathway, PPAR signaling pathway, Bacterial invasion of epithelial cells, Complement and coagu-
lation cascades, ECM-receptor interaction, Longevity regulating pathway, mRNA surveillance pathway, Circadian 
entrainment.
Discussion
We present experiments aiming to dene peripheral blood signatures of GD and GO based on circulating miR-
NAs and proteins able to discriminate between the two types of patients (GD and GO), and between aected 
individuals and healthy controls. e outlined approach made use of NGS ‘omics data (miRNA and proteomics), 
and was based on combining results from inferential and predictive statistics: dierential expression analysis was 
conducted to understand which proteins and miRNAs are up- or down-regulated in relation with the disease; 
‘omics data were used to predict to which class (GD, GO, control) individual samples belonged and, coupled with 
Lasso variable selection, specic proteins and miRNA most relevant for predictions could be identied. Overall, 
results reveal dierential expression of blood miRNA and proteins between GD and GO patients and healthy 
controls. Biomarkers have been identied, which may be used for early diagnosis and prognosis of GD, including 
the likelihood of its progression to GO.
Combining results from inference and predictions, especially if leveraging data resampling techniques, 
is a powerful approach to detecting more robust signals of associations. In the eld of genomics, combining 
Figure 3. Euler Diagram of candidate biomarkers (miRNAs and proteins) detected with dierent approaches. 
mirDE, protDE: dierential expression analysis for miRNAs and proteins. mirPRD, protPRD, mir+protPRD: 
predictive models based on miRNAs, proteins and miRNAs plus proteins (plus covariates). e intersections 
(N:1+4=5; 10+7=17; 10+1+4=15) provided the biomarkers selected for follow-up functional analysis in 
this paper: the hypothesis is that such biomarkers, identied consistently across dierent approaches, should be 
the most robust results.
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results from GWAS and from genomic predictions has been proposed to address the issue of spurious genetic 
marker-phenotype associations and produce more meaningful results47–49 or, reverting perspective, to increase 
the accuracy of genomic predictions50. Especially if the accuracy of predictions is high, selected variables from 
predictive models are likely to play a role in the studied phenotype, and can eectively contribute to identifying 
robust biomarkers associated with the disease. When using proteins and miRNAs combined, the overall accuracy 
of predictions was as high as 0.86 (0.78, 0.93 and 0.86 in GD, GO and controls respectively), with little variation, 
which points to reliable results and to a high degree of condence to be placed in the biomarkers detected through 
Lasso variable selection. Additionally, blood proteins and circulating miRNAs, with respect to GD and GO seem 
to be rather independent sources of information, as shown by the clear improvements obtained both in cluster-
ing and predictions when using all data together rather than proteins or miRNAs separately. However, although 
combining proteomics and miRNA data clearly increased the classication accuracy, the main clustering eect 
appeared to be played by blood proteins, with a lower role of circulating miRNA. is may be related to a larger 
inuence of the thyroid function on the protein metabolism.
Some relevant aspects of the methodology and results are discussed below. First, the functions of the detected 
biomarkers are discussed and placed in the context of related literature, followed by a comparison with biomark-
ers for GD from previous studies. en, the relationship between the ‘omics-based peripheral blood signature of 
GD and GO and the clinical features of patients is examined. Finally, the role of smoking habit as risk factor for 
GD is addressed.
We identied 5 miRNAs and 20 proteins combining DE and prediction models, as the most relevant bio-
markers able to help distinguish either GD or GO from controls, or between GD and GO patients. ese were 
Novel:19_15038 miRNA and Novel:hsa-miR-182-5p, both up-regulated in GO. Known miRNAs were identied 
by DE analysis, but not from the prediction model–although aberrant miRNA expression may go beyond being 
a biomarker and contribute to pathogenesis, as has been reported for cancer23. Amongst robustly identied pro-
teins, Zonulin was about 8-fold and 5-fold up-regulated in GD and GO, respectively, compared to controls, and 
about 3-fold up-regulated in GD compared to GO. Zonulin was previously associated with impaired intestinal 
tight-junctions and increased gut permeability51, and was found to be involved in autoimmune conditions, like 
type 1 diabetes52. Could zonulin upregulation have driven our identication of the “bacterial invasion of epi-
thelial cells” pathway? Over-expression of zonulin could impair gut permeability and lead to the presentation of 
environmental antigens (such as bacterial antigens) within the gut epithelial and GALT. e association between 
gut microbiome and thyroid autoimmunity has been recently proposed53,54. Celiac disease is also characterized 
by the presence of an impaired gut permeability; whether GD and celiac disease in this cohort of GD patients 
genes qvalue proportion notes
Novel:19_15038 5.96e-15 0.98 novel
Novel:hsa-miR-182-5p 4.66e-04 0.59 novel
Novel:hsa-miR-22-3p 1.69e-11 0.95 novel
Novel:hsa-miR-27a-3p 9.53e-06 0.26 novel
Novel:hsa-miR-6748-3p 2.04e-03 0.98 novel
O43157 4.94e-04 0.59 Plexin-B1
P00450 3.31e-05 0.13 Ceruloplasmin
P00738 5.39e-08 0.99 Haptoglobin
P01023 6.90e-07 0.99 Alpha-2-macroglobulin
P02652 2.10e-03 0.76 Apolipoprotein A-II
P02671 1.23e-02 0.19 Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain]
P02749 2.42e-06 0.27 Beta-2-glycoprotein 1
P02751 1.02e-03 0.13 Fibronectin
P04220 1.71e-02 0.06 Ig mu heavy chain disease protein
P04278 1.41e-04 0.71 Sex hormone-binding globulin
P19823 1.24e-05 0.15 Inter-alpha-trypsin inhibitor heavy chain H2
P22792 8.11e-03 0.14 Carboxypeptidase N subunit 2
P32119 6.58e-03 0.72 Peroxiredoxin-2
P36980 3.02e-02 0.06 Complement factor H-related protein 2
Q06609 2.59e-03 0.17 DNA repair protein RAD51 homolog 1
Q13797 8.73e-03 0.07 Integrin alpha-9
Q8WZ42 6.58e-03 0.07 Titin
Q9HBY8 1.68e-04 0.87 Serine/threonine-protein kinase Sgk2
Q9NS91 3.23e-02 0.13 E3 ubiquitin-protein ligase RAD18
Q9P217 7.12e-03 0.41 Zinc nger SWIM domain-containing protein 5
Table 3. Robust blood biomarkers for GD and GO identied from dierential expression and classication 
models. ese included 5 miRNA (all novel) and 20 proteins. e gene name or Uniprot identier are reported 
in the rst column for miRNA and proteins, respectively.
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are associated is under investigation. Several brosis-related proteins were identied as biomarkers including 
Fibronectin, Plexin-B1, Fibrinogen alpha-chain, Lumican. Interestingly, alpha 2 macroglobulin and haptoglobin 
are known to act as markers of brosis in the liver, and together with ApoA-I and some key liver enzymes are 
being used in algorithms that stage liver brosis and predict its progression55,56. Upregulation of these protein 
might occur in the process leading to brosis of the orbital tissues in GO. Metabolic and functional pathways in 
which candidate biomarkers are involved, both miRNA targets and proteins, have been retrieved from biological 
databases. Several signaling cascades have been identied, in particular, the PI3k-Akt, mTOR, FoxO, PPAR and 
the adipocytokine signaling pathways57,58. e PI3K-Akt pathway is activated by TSH-TSHR binding and its role 
in promoting orbital adipogenesis in GO patients has been described59. e peroxisome proliferator-activated 
receptor (PPAR) signaling pathway was associated with thyroid-eye disease progression60. Several pathways asso-
ciated with hypertrophic cardiomyopathy were also identied, which may be associated with the additional strain 
imposed on the cardio-circulatory system by hyperthyroidism.
Besides the candidate biomarkers identied by combining inferential and predictive results, additional blood 
proteins and miRNAs, which are known in literature to be associated with GD, were identied from either the dif-
ferential expression analysis or the resampled predictive model (though not from both). Proteins identied from 
previous studies include β-2 microglobulin, proline rich protein-4, lysozyme C and zinc α-2 glycoprotein26,27. 
Zinc α-2 glycoprotein was found to be signicantly dierentially expressed between GD, GO and controls also in 
this study, with FDR=5.39⋅10−8: in particular, it was upregulated in GD and GO patients compared to controls, 
less in GO than in GD patients. Baker and colleagues (2006) reported increased Zinc α-2 glycoprotein in the 
tears of GO patients and smokers compared with healthy controls and non-smokers. Another protein of interest 
is the lumican, a keratan sulphate proteoglycan expressed in the cornea and mesenchymal tissues throughout the 
body and has been reported to be associated with orbital brosis61. Higher levels of adiponectin and the sex hor-
mone binding globulin (SHBG) in GD patients conrmed data from a previous study62. e hyaluronan binding 
protein, the retinol binding protein and the vitamin D binding protein–slightly over-expressed in GD and GO 
compared to controls–were, as previously reported, associated with the disease status in GD and GO. miRNA 
Figure 4. Heatmap of the log2 Fold Change (logFC) of candidate robust biomarkers listed in Table 3. Across 
group-comparisons: GD vs. controls (HC), GO vs. HC and GO vs. GD. logFC values are taken from dierential 
expression (DE) analysis. Change in colour intensity refers to change in the expression of biomarkers in the 
three comparisons: red, positive logFC, up-regulation; blue, negative logFC, down-regulation.
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associated with Graves disease have been reported in literature63,64. ese did not match with biomarkers identi-
ed in the present study, possibly due to the dierent biological tissues (PBMC -peripheral blood monocytes- vs 
blood) or technology (miRNA microarrays or quantitative RT-PCR).
Since in most cases protein expression was higher in GD patients than GO or healthy controls, possibly reect-
ing their hyperthyroid status, circulating miRNAs and protein proles were related to thyroid-receptor antibody 
(TRAB) titres, thyroid-stimulating hormone (TSH) and free thyroxine (FT4) concentrations, and hyperthyroid/
euthyroid status using canonical correspondence analysis65. e hyperthyroid/euthyroid status, clinically deter-
mined and conrmed by biochemical testing, was superimposed on the distance matrix based on blood miRNA 
and protein counts. Results (Fig. 6) showed that GD and GO patients were hyperthyroid, and controls euthyroid; 
accordingly, TRAB positivity was detected in GD and GO patients. is is consistent with Graves’ disease: TRAB 
Figure 5. Top metabolic pathways (from KEGG) enriched in the genes associated with the candidate 
biomarkers for Graves’ disease and orbitopathy detected using blood proteins, blood miRNAs or both.
Description p-value exp
Hippo signaling pathway - multiple species 0.003 miRNA
Oxytocin signaling pathway 0.008 miRNA
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.016 miRNA
Longevity regulating pathway 0.024 miRNA
mRNA surveillance pathway 0.025 miRNA
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.003 miRNA+proteomics
Hypertrophic cardiomyopathy (HCM) 0.005 miRNA+proteomics
Dilated cardiomyopathy (DCM) 0.006 miRNA+proteomics
Hippo signaling pathway - multiple species 0.006 miRNA+proteomics
Regulation of actin cytoskeleton 0.010 miRNA+proteomics
Complement and coagulation cascades 0.005 proteomics
ECM-receptor interaction 0.005 proteomics
Hypertrophic cardiomyopathy (HCM) 0.005 proteomics
Dilated cardiomyopathy (DCM) 0.006 proteomics
PI3K-Akt signaling pathway 0.010 proteomics
Table 4. Top 5 pathways per analysis (miRNA, proteins, miRNA+proteins) associated with the identied 
biomarkers for Graves’ disease and orbitopathy (Table eab:biomarkers). Results based on the KEGG database 
of human genes and metabolic pathways. Pathways are grouped per experiment (using gene symbols from 
proteomics, from miRNA targets, and from both proteomics and miRNA targets).
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stimulate the thyroid to produce FT4 (and FT3) which, in turn, exert a negative feedback on TSH release from the 
pituitary gland. In particular, GD patients tended to be more hyperthyroid (lower TSH and higher FT4) than GO. 
e likely explanation is that GO patients are usually prescribed with anti-thyroid treatment promptly following 
the diagnosis, in order to avoid further worsening of the eye condition due to the thyroid dysfunction. It was 
reassuring to note that samples did not cluster entirely according to thyroid status suggesting that the dierential 
expressions observed are also driven by immune as well as endocrine factors. is is supported by the work of 
Pietzner and colleagues66 who devised an experimental model of human hyperthyroidism and reported that sev-
eral of the proteins detected in our study, e.g. lumican, bronectin were aected by FT4, but not all e.g. zonulin.
Smoking habit is known to be related to GO67. Smoking was recorded from the individuals recruited for this 
study (Table 1): smokers were prevalently distributed in patients rather than controls (15:1). e frequency of 
smokers was higher in GO than in GD patients (9:6). Smoking habit appears to be quite confounded with disease 
status, and one may wonder whether some of the detected biomarkers are actually associated with smoking rather 
than the disease. Results from literature, however, show that none of the reported blood biomarkers for smoking 
habit4,68,69, nor dierentially expressed lung proteins between smokers and non-smokers70 or genes associated 
with smoking from GWAS71, match the biomarkers for GD and GO identied in this study. is helps dispel 
concerns on possible confounding of detected biomarkers between Graves’ disease and smoking habit.
e study would have beneted from the inclusion of healthy controls who were smokers. Other limitations 
include the small number of patients and controls analyzed and the lack of a group having non-autoimmune 
hyperthyroidism to distinguish eects driven by immune or endocrine factors. e focus on women subjects, in 
addition to being relevant to the disease, also eliminated confounding eects of hormones.
To summarize, an approach combining predictive and inferential statistics was adopted for the discovery of 
blood biomarkers associated with Graves’ disease and orbitopathy from a miRNA and proteomics sequencing 
experiment. A total of 25 robust circulating biomarkers have been identied (5 novel miRNAs, 20 proteins), 
potentially able to discriminate between healthy controls, GD and GO patients. e biological functions of these 
biomarkers have also been investigated, highlighting interesting connections with brosis and gut permeability 
(and autoimmunity onset). e identied blood biomarkers may be a helpful tool for clinicians to be used for 
early diagnosis of Graves’ disease, and for the prognosis of the disease, including the likelihood of developing 
orbitopathy, and represent a step forward in the direction of technology-driven precision medicine72.
References
1. Glassman, R. & Ratain, M. Biomarkers in Early Cancer Drug Development: Limited Utility. Clinical Pharmacology & erapeutics
134–135 (2009).
2. Holmes, E., Wilson, I. D. & Nicholson, J. K. Metabolic phenotyping in health and disease. Cell 134, 714–717 (2008).
3. Shah, S. H., Kraus, W. E. & Newgard, C. B. Metabolomic proling for the identication of novel biomarkers and mechanisms related 
to common cardiovascular diseases form and function. Circulation 1110–1120 (2012).
4. Rosas, I. O. et al. Mmp1 and mmp7 as potential peripheral blood biomarkers in idiopathic pulmonary brosis. PLoS medicine 5, e93 
(2008).
5. Wong, Y. H. et al. Applying NGS data to nd evolutionary network biomarkers from the early and late stages of hepatocellular 
carcinoma. BioMed Research International 1–27 (2015).
6. Snyder, A. et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelialb 
cancer: An exploratory multi-omic analysis. PLoS Medicine e1002309 (2017).
7. Nassirpour, R. et al. Identication of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and 
qPCR-based proling platforms. BMC Genomics 485 (2014).
8. Michael, A. et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Diseases 34–38 (2010).
9. Peng, F. et al. Identication of microRNAs in throat swab as the biomarkers for diagnosis of inuenza. International Journal of 
Medical Sciences 77–84 (2016).
Figure 6. (a) Canonical correspondence analysis (CCA) plot of ‘omics-based Euclidean distances between 
samples and their quantitative clinical features (TSH, TRAB and FT4 levels). (b) Multidimensional scaling plot 
of miRNA+proteomics distances with superimposed hyperthyroidism status (euthyroid vs. hyperthyroid).
www.nature.com/scientificreports/
3SCIENTIFIC REPORTS |  (2018) 8:8386  | DOI:10.1038/s41598-018-26700-1 1
10. Hasan, N., McColgan, P., Bentley, P., Edwards, R. J. & Sharma, P. Towards the identication of blood biomarkers for acute stroke in 
humans: A comprehensive systematic review. British Journal of Clinical Pharmacology 230–240 (2012).
11. Shoki, A. H., Mayer-Hamblett, N., Wilcox, P. G., Sin, D. D. & Quon, B. S. Systematic review of blood biomarkers in cystic brosis 
pulmonary exacerbations. Chest 144, 1659–1670 (2013).
12. Shou, J. et al. Identication of blood biomarkers of rheumatoid arthritis by transcript proling of peripheral blood mononuclear cells 
from the rat collagen-induced arthritis model. Arthritis research & therapy R28 (2006).
13. Bogdanov, M. et al. Metabolomic proling to develop blood biomarkers for Parkinson’s disease. Brain 389–396 (2008).
14. Vij, R. & Noth, I. Peripheral blood biomarkers in idiopathic pulmonary brosis. Translational Research 159, 218–227 (2012).
15. Fischer, K. et al. Biomarker Proling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An 
Observational Study of 17,345 Persons. PLoS Medicine e1001606 (2014).
16. Lombardi, A. et al. Dissecting the genetic susceptibility to graves’ disease in a cohort of patients of Italian origin. Frontiers in 
endocrinology 7, 21 (2016).
17. Lee, H. J. et al. Cd40 signaling in graves disease is mediated through canonical and noncanonical thyroidal nuclear factor κ b 
activation. Endocrinology 158, 410–418 (2016).
18. Lazarus, J. H. Epidemiology of graves’ orbitopathy (go) and relationship with thyroid disease. Best Practice & Research Clinical 
Endocrinology & Metabolism 26, 273–279 (2012).
19. Tanda, M. L. et al. Prevalence and natural history of graves’ orbitopathy in a large series of patients with newly diagnosed graves’ 
hyperthyroidism seen at a single center. Journal of Clinical Endocrinology and Metabolism 1443–1449 (2013).
20. Eckstein, A. K. et al. yrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves’ Ophthalmopathy and Help to 
Predict Severity and Outcome of the Disease. e Journal of Clinical Endocrinology & Metabolism 3464–3470 (2006).
21. Khoo, D. H. et al. e combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in 
Graves’ disease identies a group at markedly increased risk of ophthalmopathy. yroid: ocial journal of the American yroid 
Association 1175–80 (1999).
22. Novák, J., Olejníčková, V., Tkáčová, N. & Santulli, G. Mechanistic role of micrornas in coupling lipid metabolism and atherosclerosis. 
In microRNA: Basic Science, 79–100 (Springer, 2015).
23. Calin, G. A. & Croce, C. M. Chromosomal rearrangements and micrornas: a new cancer link with clinical implications. e Journal 
of clinical investigation 117, 2059–2066 (2007).
24. Jiang, L. H. & Wei, R. L. Analysis of Graves’ ophthalmopathy patients’ tear protein spectrum. Chinese Medical Journal 4493–4498 
(2013).
25. Matheis, N., Okrojek, R., Grus, F. H. & Kahaly, G. J. Proteomics of Tear Fluid in yroid-Associated Orbitopathy. yroid 1039–1045 
(2012).
26. Aass, C. et al. Comparative proteomic analysis of tear uid in Graves’ disease with and without orbitopathy. Clinical Endocrinology
805–812 (2016).
27. Baker, G. R. C. et al. Altered tear composition in smokers and patients with graves ophthalmopathy. Archives of ophthalmology
1451–6 (2006).
28. Matheis, N. et al. Proteomics Differentiate Between Thyroid-Associated Orbitopathy and Dry Eye Syndrome. Investigative 
Opthalmology & Visual Science 2649 (2015).
29. Shen, L. et al. Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves’ ophthalmopathy. Endocrine 445–456 
(2015).
30. Bartalena, L. et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. 
European Journal of Endocrinology 273–285 (2008).
31. Lucini, L. & Bernardo, L. Comparison of proteome response to saline and zinc stress in lettuce. Frontiers in plant science 240 (2015).
32. Ewing, B. et al. Base-Calling of Automated Sequencer Traces Using. Genome Research 175–185 (2005).
33. Friedländer, M. R., Mackowiak, S. D., Li, N., Chen, W. & Rajewsky, N. miRDeep2 accurately identies known and hundreds of novel 
microRNA genes in seven animal clades. Nucleic Acids Research 37–52 (2012).
34. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. 
Genome Biology R29 (2014).
35. Napier, J. Mirici logarithmorum canonis descriptio - John Napier - Google Books (Hart) (1614).
36. Cox, M. A. A. & Cox, T. F. Multidimensional Scaling. In Handbook of Data Visualization, 315–347 (Springer Berlin Heidelberg, 
Berlin, Heidelberg) (2008).
37. Storey, J. D. False Discovery Rate. In International Encyclopedia of Statistical Science, 504–508 (Springer Berlin Heidelberg, Berlin, 
Heidelberg) (2011).
38. Hart, S. N., erneau, T. M., Zhang, Y., Poland, G. A. & Kocher, J.-P. Calculating Sample Size Estimates for RNA Sequencing Data. 
Journal of Computational Biology 970–978 (2013).
39. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. Journal of 
Statistical Soware 1–22 (2010).
40. Stone, M. Cross-validatory choice and assessment of statistical predictions. Journal of the royal statistical society. Series B 
(Methodological) 111–147 (1974).
41. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. Journal of Molecular Biology
403–410 (1990).
42. Andrews, S. FastQC: a quality control tool for high throughput sequence data (2010).
43. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A exible trimmer for Illumina sequence data. Bioinformatics 2114–2120 
(2014).
44. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for dierential expression analysis of digital gene 
expression data. Bioinformatics 139–140 (2010).
45. Bass, A. J., Dabney, A. & Robinson Maintainer John Storey, D. D. Q-value estimation for false discovery rate control (2016).
46. Wickham, H. Ggplot2: elegrant graphics for data analysis (2016).
47. Biani, S. et al. Predicting haplotype carriers from snp genotypes in bos taurus through linear discriminant analysis. Genetics 
selection evolution 47, 4 (2015).
48. Biscarini, F., Biani, S. & Stella, A. Más allá del GWAS: alternativas para localizar QTLs. arXiv 1–5 (2015).
49. Biscarini, F. et al. Use of snp genotypes to identify carriers of harmful recessive mutations in cattle populations. BMC genomics 17, 
857 (2016).
50. Zhang, Z. et al. Improving the accuracy of whole genome prediction for complex traits using the results of genome wide association 
studies. PLoS ONE e93017 (2014).
51. Fasano, A. Zonulin and Its Regulation of Intestinal Barrier Function: e Biological Door to Inammation, Autoimmunity, and 
Cancer. Physiological Reviews 151–175 (2011).
52. Sapone, A. et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their 
relatives. Diabetes 1443–1449 (2006).
53. Covelli, D. & Ludgate, M. e thyroid, the eyes and the gut: a possible connection. Journal of endocrinological investigation 40, 
567–576 (2017).
www.nature.com/scientificreports/
2SCIENTIFIC REPORTS |  (2018) 8:8386  | DOI:10.1038/s41598-018-26700-1 1 4
54. Köhling, H. L., Plummer, S. F., Marchesi, J. R., Davidge, K. S. & Ludgate, M. e microbiota and autoimmunity: eir role in thyroid 
autoimmune diseases. Clinical Immunology 183, 63–74 (2017).
55. Naveau, S., Poynard, T., Benattar, C., Bedossa, P. & Chaput, J. C. Alpha-2-macroglobulin and hepatic brosis - Diagnostic interest. 
Digestive Diseases and Sciences 2426–2432 (1994).
56. Rossi, E., Adams, L. A., Bulsara, M. & Jerey, G. P. Assessing liver brosis with serum marker models. Clin Biochem Rev 3–10 (2007).
57. Morshed, S. A., Latif, R. & Davies, T. F. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology
519 (2009).
58. Zhang, L. et al. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves’ 
orbitopathy. Journal of Clinical Endocrinology and Metabolism 653–662 (2012).
59. Kumar, S., Nadeem, S., Stan, M. N., Coenen, M. & Bahn, R. S. A stimulatory TSH receptor antibody enhances adipogenesis via 
phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. Journal of Molecular 
Endocrinology 155–163 (2011).
60. Zhang, L., Paddon, C., Lewis, M. D., Grennan-Jones, F. & Ludgate, M. Gs-alpha signalling suppresses PPAR-gamma2 generation and 
inhibits 3T3L1 adipogenesis. Journal of Endocrinology 207–215 (2009).
61. Rosenbaum, J. T. et al. Fibrosis, gene expression and orbital inammatory disease. e British journal of ophthalmology 1424–9 
(2015).
62. Siemińska, L. et al. Relationships between adiponectin, sex hormone binding globulin and insulin resistance in hyperthyroid graves’ 
disease women. Endokrynologia Polska 64, 26–29 (2013).
63. Liu, R. et al. Dierential MicroRNA Expression in Peripheral Blood Mononuclear Cells from Graves’ Disease Patients. e Journal 
of Clinical Endocrinology & Metabolism E968–E972 (2012).
64. Wang, Z. et al. Integrative Analysis of mRNA and miRNA Array Data Reveals the Suppression of Retinoic Acid Pathway in 
Regulatory T Cells of Graves’ Disease. e Journal of Clinical Endocrinology & Metabolism E2620–E2627 (2014).
65. Ter Braak, C. J. Canonical correspondence analysis: a new eigenvector technique for multivariate direct gradient analysis. Ecology
67, 1167–1179 (1986).
66. Pietzner, M. et al. Plasma proteome and metabolome characterization of an experimental human thyrotoxicosis model. BMC 
Medicine 6 (2017).
67. Wiersinga, W. M. Smoking and thyroid. Clinical endocrinology 79, 145–151 (2013).
68. van Leeuwen, D. M. et al. Dierential gene expression in human peripheral blood mononuclear cells induced by cigarette smoke and 
its constituents. Toxicological Sciences 200–210 (2005).
69. van Leeuwen, D. M. et al. Cigarette smoke-induced dierential gene expression in blood cells from monozygotic twin pairs. 
Carcinogenesis 691–7 (2007).
70. Landi, M. T. et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. 
PLoS ONE e1651 (2008).
71. Furberg, H. et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nature Genetics 441–447 
(2010).
72. Su, M. Y. & Fisher, D. E. Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLOS Medicine e1002196 (2016).
Acknowledgements
is work was supported by Marie-Sklodowska Curie Industry Industry-Academia Pathways and Partnerships 
(IAPP) action, GA number 612116 project INDIGO. Additional members of the Indigo consortium are 
acknowledged for their contribution: S. Plummer, D. Michael, I. Garaiova, J. Marchesi, H. Koehling, S. 
Moshkelgosha, U. Berchner-Pfannschmidt.
Author Contributions
F.B., L.L. and M.L. conceived and designed the study. Patients were recruited and managed by A.E., U.K., M.S., 
D.C., I.M. and S.D. L.Z. and G.M. acquired the data. L.Z., L.L., G.M. and F.B. prepared and analysed the data, with 
interpretation by M.L., G.C., M.S., D.C., A.E. and U.K. F.B. and M.L. wrote the rst dra of the manuscript, all 
authors critically appraised and revised it.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-26700-1.
Competing Interests: e authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional aliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. e images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© e Author(s) 2018
